Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Adulterated supplement linked to kidney failure

This article was originally published in The Tan Sheet

Executive Summary

U.K. regulatory agencies say the turmeric-based food supplement Miradin/Fortodol may contain the undeclared drug nimesulide and warn consumers against using the product. The Medicines and Healthcare products Regulatory Agency and the Food Standards Agency warn adulterated Fortodol may cause liver damage. The warnings follow an announcement by the Swedish Medical Products Agency that the product is linked to at least 11 reports of liver damage and potentially two deaths. Nimesulide is a potent anti-inflammatory drug not authorized for sale as a medicine in the U.K. The American firm Donsbach makes the supplement and exports it to Sweden where it is resold across Europe, according to the U.K. agencies

You may also be interested in...

Digital And AI Capabilities Essential For Diagnostic Success Says German Industry

The value of rare disease research must not be overlooked as the drive to diagnose and contain coronavirus mounts.

England’s NICE Recommends BMS/Celgene’s Revlimid For Follicular Lymphoma

Health technology assessment body NICE says that Revlimid fights cancer cells in a different way to current treatments which should help reduce resistance and improve disease outcomes.

Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal

As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts